Dr. Reddy's Laboratories Limited (RDY)
Automate Your Wheel Strategy on RDY
With Tiblio's Option Bot, you can configure your own wheel strategy including RDY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RDY
- Rev/Share 411.216
- Book/Share 435.1727
- PB 2.7784
- Debt/Equity 0.1634
- CurrentRatio 1.852
- ROIC 0.1263
- MktCap 996412912635.348
- FreeCF/Share 37.4392
- PFCF 31.9865
- PE 16.991
- Debt/Assets 0.1081
- DivYield 0.0068
- ROE 0.1725
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RDY | HSBC Securities | Hold | Buy | -- | $16.9 | June 5, 2025 |
| Downgrade | RDY | Nomura | Buy | Neutral | -- | -- | Dec. 19, 2024 |
News
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds
Published: October 29, 2025 by: Seeking Alpha
Sentiment: Positive
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, with North America lagging but Europe and emerging markets offsetting declines through acquisitions and new launches. Key growth drivers include upcoming biosimilar Abatacept and generic GLP-1 drugs, with launches expected to boost earnings beyond FY27 as Revlimid headwinds subside.
Read More
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Read More
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2026 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Richa Periwal - Head of Investor Relations and Analytics Mannam Venkatanarasimham - CFO & Member of the Management Council Erez Israeli - CEO & Member of the Management Council Conference Call Participants Neha Manpuria - BofA Securities, Research Division Damayanti Kerai - HSBC Global Investment Research Bino Pathiparampil - Elara Securities (India) Private Limited, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Madhav Marda - Fidelity Investments Kunal Dhamesha - Macquarie Research Tushar Manudhane - Motilal Oswal Securities Limited, …
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Extrovis AG Bahnhof Park 46340, Baar, Switzerland Media Relations Contact Madhu Marur [email protected] Press Release Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. …
Read More
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Read More
Dr. Reddy's Q1FY26 Financial Results
Published: July 23, 2025 by: Business Wire
Sentiment: Neutral
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.
Read More
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.
Read More
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).
Read More
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.
Read More
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Read More
Dr. Reddy's Q4 & Full Year FY25 Financial Results
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.
Read More
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.
Read More
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
Read More
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
Published: March 13, 2025 by: Business Wire
Sentiment: Neutral
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.
Read More
About Dr. Reddy's Laboratories Limited (RDY)
- IPO Date 2001-04-11
- Website https://www.drreddys.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Erez Israeli
- Employees 27048